Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

Strauss, 1992, Epstein-Barr virus infections: biology, pathogenesis and management, Ann Intern Med, 118, 45, 10.7326/0003-4819-118-1-199301010-00009

List, 1987, Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein Barr virus, J Clin Oncol, 5, 1673, 10.1200/JCO.1987.5.10.1673

Joske, 1993, Epstein-Barr virus in Lymphomas: a review, Blood Rev, 7, 215, 10.1016/0268-960X(93)90008-R

Cohen, 1991, Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency, Proc Natl Acad Sci USA, 86, 9558, 10.1073/pnas.86.23.9558

Klein, 1994, Epstein-Barr virus strategy in normal and neoplastic B cells, Cell, 77, 791, 10.1016/0092-8674(94)90125-2

Papadopoulos, 1994, Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogenic bone marrow transplantation, N Engl J Med, 330, 1185, 10.1056/NEJM199404283301703

Heslop, 1994, Donor T cells as therapy for EBV lymphoproliferation post bone marrow transplant, N Engl J Med, 331, 679

Heslop, 1994, Administration of neomycin resistance gene marked EBV specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts, Hum Gene Ther, 5, 381, 10.1089/hum.1994.5.3-381

Rickinson, 1981, Long-term cell-mediated immunity to Epstein-Barr virus, Cancer Res, 41, 4216

Brenner, 1993, Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients, Lancet, 342, 1134, 10.1016/0140-6736(93)92122-A

Boyle, 1991, Sub types of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma, Blood, 78, 3004, 10.1182/blood.V78.11.3004.3004

Zimber, 1986, Geographical prevalence of two types of Epstein-Barr virus, Virology, 154, 56, 10.1016/0042-6822(86)90429-0

Savoie, 1994, Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease, Blood, 83, 2715, 10.1182/blood.V83.9.2715.2715

Riddler, 1994, Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody response are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients, Blood, 84, 972, 10.1182/blood.V84.3.972.972

Cm Rooney, Sk Loftin, Ms Holladay, Mk Brenner, Ra Krance, He Heslop, Early prediction of EBV associated post-transplant lymphoproliferative disease, Br J Haematol ((in press)).

Heslop, 1994, Epstein-Barr infection after bone marrow transplantation, Blood, 83, 1706, 10.1182/blood.V83.6.1706b.1706b

Prentice, 1984, Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients, Lancet, i, 472, 10.1016/S0140-6736(84)92848-4

Kolb, 1990, Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant recipients, Blood, 76, 2462, 10.1182/blood.V76.12.2462.2462

van Rhee, 1994, Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse, Blood, 83, 3377, 10.1182/blood.V83.11.3377.3377

Riddell, 1992, Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones., Science, 257, 238, 10.1126/science.1352912

Crawford, 1986, Epstein-Barr virus infection and immunity in bone marrow transplant recipients, Transplantation, 42, 50, 10.1097/00007890-198607000-00010

Duncombe, 1992, Bone marrow transplant recipients have defective MHC-unrestricted cytotooxic response against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1), Blood, 79, 3059, 10.1182/blood.V79.11.3059.3059

Fischer, 1991, Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliverative syndrome following bone marrow and organ transplantation, N Engl J Med, 324, 1451, 10.1056/NEJM199105233242102

Murray, 1992, Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies, J Exp Med, 176, 157, 10.1084/jem.176.1.157

Khanna, 1992, Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development, J Exp Med, 176, 169, 10.1084/jem.176.1.169

Bourgault, 1991, Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes, Clin Exp Immunol, 84, 501

Burrows, 1994, An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease, J Exp Med, 179, 1155, 10.1084/jem.179.4.1155

Lieberman, 1994, Using T cells to treat B-cell cancers, N Engl J Med, 330, 1231, 10.1056/NEJM199404283301711

Young, 1992, Epstein-Barr virus, lymphomas and Hodgkin's disease, Semin Cancer Biol, 3, 273